Masimo (MASI) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Masimo Corp  (NASDAQ: MASI)

Select the Financial Report: Select the Period:


Description of Masimo's Business Segments


Masimo Corp is a leading global innovator in noninvasive monitoring technologies that enhance patient safety and improve clinical outcomes. The companys operations are categorized into two primary segments, each of which encompasses a diverse range of products and services designed for both medical professionals and patients.

Segments:

1. Masimo Signal Extraction Technology (SET) Segment:
- The Masimo SET Segment is focused on the development, manufacturing, and sales of a suite of pulse oximetry products that leverage proprietary Signal Extraction Technology. This technology enhances the accuracy and reliability of noninvasive measurements, enabling precise monitoring of patients in various settings, including hospitals, ambulatory surgical centers, and home healthcare environments. The products in this segment provide critical information by measuring:
- Arterial Oxygen Saturation (SpO2): The percentage of oxygen-saturated hemoglobin in the blood.
- Pulse Rate: The number of heartbeats per minute.
- Signal Quality: An assessment of the quality of the signal received, which reflects the reliability of the measurement.

2. Masimo Noninvasive Patient Monitoring (NPM) Segment:
- This segment includes a comprehensive range of noninvasive monitoring technologies, particularly the Masimo Rainbow SET Pulse CO-Oximetry products. These advanced systems enable healthcare providers to measure multiple blood parameters without invasive procedures, which is essential for the monitoring of patients’ health status. Key features of this segment include:
- Hematology parameters: Measurements of hemoglobin levels, which are critical for diagnosing conditions like anemia.
- Oxygen Saturation: Accurate monitoring of blood oxygen levels.
- Carboxyhemoglobin and Methemoglobin levels: Monitoring for carbon monoxide exposure and other hemoglobin variants, facilitating the management of potential poisoning or other respiratory conditions.

Products:

- Masimo SET Pulse Oximetry Products:
- These products cater to diverse clinical environments with multiple models optimized for various applications. They are designed to provide reliable and accurate readings for healthcare professionals managing patients in critical care, operating rooms, emergency departments, and general medical wards, as well as for home healthcare situations.

- Masimo Rainbow SET Pulse CO-Oximetry Products:
- This product line extends the capabilities of pulse oximetry, enabling healthcare professionals to obtain comprehensive information about a patient’s blood composition and condition. It is particularly useful for diagnosing and managing complex medical conditions such as respiratory complications, chronic lung diseases, and instances of suspected carbon monoxide poisoning.

- Root Patient Monitoring and Connectivity Platform:
- The Root platform integrates various monitoring devices and allows for real-time data consolidation. It supports clinicians in making informed decisions with an automated evaluation of clinical parameters and metrics. This platform not only enhances patient assessment and monitoring but also aids in increasing overall clinical efficiency by streamlining data access and management across different care settings.

Services:

- Masimo Patient SafetyNet:
- This advanced service provides a robust framework for remote patient monitoring. SafetyNet enables continuous surveillance of patients physiological parameters and instantly alerts healthcare providers to any significant changes in a patient’s condition. By facilitating proactive intervention, this service is instrumental in enhancing patient safety and reducing critical event occurrences.

- Masimo Education and Training:
- Masimo is deeply committed to the education and training of healthcare professionals. The company offers a variety of learning resources, including online training modules, live webinars, video tutorials, and hands-on training sessions. These educational initiatives are geared towards ensuring that medical personnel are proficient in utilizing Masimo’s innovative technologies effectively, ultimately aimed at improving patient care outcomes.

- Masimo Connectivity Services:
- This service enhances the efficiency of clinical workflows by ensuring seamless integration of patient physiological data with electronic health record systems, third-party applications, and Masimos proprietary patient management systems. The secure transfer of data is critical for clinical decision-making, retrospective analysis, and longitudinal patient management, thus enabling healthcare providers to deliver better-informed, data-driven care.

In summary, Masimo Corp offers a comprehensive portfolio of noninvasive monitoring solutions and educational support aimed at enhancing patient care across various healthcare settings. Their innovations not only empower clinicians with vital patient data but also contribute to improved clinical outcomes and operational efficiencies.


Composition of Masimo Corp Revenues by Segments

 
Healthcare    99.95 % of total Revenue
Other    0.25 % of total Revenue

Q1 three months ended (Apr 04 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Healthcare 402.60 99.95 %
Other 1.00 0.25 %
Total 402.80 100 %




Q1 three months ended (Apr 04 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Healthcare 8.52 % -
Other 0 % -
Total 8.28 % -73.61 %




Q1 three months ended (Apr 04 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Healthcare 250.80 62.3 %
Total 57.10 14.18 %




Q1 three months ended (Apr 04 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Healthcare 7.13 % -
Total - -




Annual Report on Masimo Corp Divisions, Sales by Country

 
Healthcare   Healthcare Segment contribution to total sales 99.86 % of total Revenue
Other   Other Segment contribution to total sales 0.18 % of total Revenue
United States U S   United States U S Segment contribution to total sales 62.68 % of total Revenue
Europe Middle East and Africa   Europe Middle East and Africa Segment contribution to total sales 25.65 % of total Revenue
Asia and Australia   Asia and Australia Segment contribution to total sales 7.84 % of total Revenue
North and South America excluding U S   North and South America excluding U S Segment contribution to total sales 3.89 % of total Revenue


Twelve months ended 2025
MASI s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Healthcare 1,524.10 99.86 %
Other 2.80 0.18 %
Total 1,526.20 100 %
United States U S 956.60 62.68 %
Europe Middle East and Africa 391.40 25.65 %
Asia and Australia 119.60 7.84 %
North and South America excluding U S 59.30 3.89 %


Twelve months ended 2025
MASI s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Healthcare 950.30 62.35 %
Total -151.50 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Healthcare 9.24 % 8.67 %
Total -27.13 % -
United States U S -15.16 % -
Europe Middle East and Africa -34.28 % -
Asia and Australia -60.59 % -
North and South America excluding U S -12.41 % -
Intersegment - -
Non-healthcare - -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.